Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer materials and fuller coverage of difficult genomic regions with | Version 2 ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino ...

VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with ...

Volker Herrmann, M.D., has also stepped away from the helm, with Sonata chairman David Khougazian taking the wheel as acting ...

Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...

Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a ...

After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits ...

Philips unveiled the next generation of its MRI scanner, with sealed magnets that do not need to be recharged with liquid ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. The Big Pharma ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate. The biotech ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...